A bird's-eye view of T cells during natalizumab therapy.
From the Institute of Clinical Neuroimmunology (R.H.), Ludwig Maximilians University, Munich; Munich Cluster for Systems Neurology (SyNergy) (R.H.), Germany; and University of Texas Southwestern Medical Center and Neurology Section (O.S.), VA North Texas Health Care Systems, Dallas.
Reinhard
R
Hohlfeld
Olaf
O
Stüve
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000276:immunology*; D000069442:Natalizumab; D011948:Receptors, Antigen, T-Cell / Q000096:biosynthesis*
D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D011948:Receptors, Antigen, T-Cell